摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,7-二氮杂螺[4.4]壬烷, 2-甲基-,双盐酸盐 | 91188-26-0

中文名称
2,7-二氮杂螺[4.4]壬烷, 2-甲基-,双盐酸盐
中文别名
2-甲基-2,7-二氮杂螺[4.4]壬烷二盐酸盐;2,7-二氮杂螺[4.4]壬烷,2-甲基-,双盐酸盐
英文名称
2-Methyl-2,7-diazaspiro[4.4]nonane dihydrochloride
英文别名
2-methyl-2,7-diazaspiro[4.4]nonane;dihydrochloride
2,7-二氮杂螺[4.4]壬烷, 2-甲基-,双盐酸盐化学式
CAS
91188-26-0
化学式
C8H18Cl2N2
mdl
MFCD13185105
分子量
213.15
InChiKey
KTWQBDFIDPFQKG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    168-170℃

计算性质

  • 辛醇/水分配系数(LogP):
    -0.09
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    15.3
  • 氢给体数:
    3
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933990090

SDS

SDS:cc59360dc6ad79d8ead65c05203fdf79
查看

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES TRICYCLIQUES EN TANT QU'INHIBITEURS DE PHOSPHO-INOSITIDE 3-KINASE
    申请人:KARUS THERAPEUTICS LTD
    公开号:WO2015121657A1
    公开(公告)日:2015-08-20
    A compound of formula I: (I) or a pharmaceutically acceptable salt thereof, wherein: W is O, N-H, N-(C1 -C 10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is LY; each L is a direct bond, C1 -C 10 alkylene, C2 -C10 alkenylene or C2 -C 10 alkynylene; Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and each R3 is independently H, C1-C 10 alkyl, halogen, fluoro C1 -C10 alkyl, O- C1 -C10 alkyl, NH-C1 -C10 alkyl, S-C1 -C10 alkyl, O- fluoro C1 -C10 alkyl, NH-acyl, NH-C(O)-NH-C1 -C10 alkyl, C(O)-NH-C1 -C10 alkyl, aryl or heteroaryl, are useful as inhibitors of the class IA phosphoinositide 3- kinase enzyme, PI3K-p110δ, and therefore have potential utility in the therapy of cancer, immune and inflammatory diseases.
    一种具有以下结构式I的化合物:(I)或其药学上可接受的盐,其中:W为O、N-H、N-(C1-C10烷基)或S;每个X独立地为CH或N;R1为含有至少1个来自N或O的杂原子的5至7成员饱和或不饱和、可选择地取代的杂环;R2为LY;每个L为直接键、C1-C10烷基、C2-C10烯基或C2-C10炔基;Y为含有最多4个来自N或O的杂原子的可选择地取代的融合、桥接或螺环非芳香性5-12成员杂环;每个R3独立地为H、C1-C10烷基、卤素、代C1-C10烷基、O-C1-C10烷基、NH-C1-C10烷基、S-C1-C10烷基、O-代C1-C10烷基、NH-酰基、NH-C(O)-NH-C1-C10烷基、C(O)-NH-C1-C10烷基、芳基或杂芳基,可用作类IA磷脂酰肌醇3-激酶酶、PI3K-p110δ的抑制剂,因此在癌症、免疫和炎症性疾病的治疗中具有潜在用途。
  • [EN] COMPOSITIONS COMPRISING TRICYCLIC HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSITIONS COMPRENANT DES COMPOSÉS HÉTÉROCYCLIQUES
    申请人:KARUS THERAPEUTICS LTD
    公开号:WO2017029518A1
    公开(公告)日:2017-02-23
    The invention relates to a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical excipient selected from the group consisting of fillers, binders, disintegrants, glidants and lubricants, wherein the compound according to formula I is represented by:
    这项发明涉及一种药物组合物,包括式I的化合物或其药用可接受盐,以及从填料、粘合剂、分散剂、润滑剂和润滑剂组成的群体中选择的至少一种药用辅料,其中根据式I表示的化合物为:
  • [EN] COMPOSITIONS COMPRISING A PI3K INHIBITOR AND AN HDAC INHIBITOR<br/>[FR] COMPOSITIONS COMPRENANT UN INHIBITEUR DE PI3K ET UN INHIBITEUR DE HDAC
    申请人:KARUS THERAPEUTICS LTD
    公开号:WO2017029514A1
    公开(公告)日:2017-02-23
    The invention relates to a pharmaceutical composition comprising at least one PI3K inhibitor of Formula I or a pharmaceutically acceptable salt thereof and at least one HDAC inhibitor such as a compound of Formula II or a pharmaceutically acceptable salt thereof; or at least one PI3K inhibitor such as a compound of Formula I or a pharmaceutically acceptable salt thereof and at least one HDAC inhibitor of Formula II or a pharmaceutically acceptable salt thereof.
    该发明涉及一种药物组合物,包括至少一种式I的PI3K抑制剂或其药用可接受盐,以及至少一种HDAC抑制剂,例如式II的化合物或其药用可接受盐;或者至少一种PI3K抑制剂,例如式I的化合物或其药用可接受盐,以及至少一种式II的HDAC抑制剂或其药用可接受盐。
  • [EN] COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT<br/>[FR] COMPOSITIONS COMPRENANT DES INHIBITEURS DE LA PHOSPOINOSITIDE 3-KINASE ET UN SECOND AGENT ANTIPROLIFÉRATIF
    申请人:KARUS THERAPEUTICS LTD
    公开号:WO2017029517A1
    公开(公告)日:2017-02-23
    The invention relates to a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one second agent selected from the group consisting of signal transduction pathway inhibitors, tumour immunotherapeutics, agents inhibiting the BCL2 family of proteins, agents inhibiting Mcl-1, proteasome Inhibitors, poly (ADP-ribose) polymerase (PARP) Inhibitors, aromatase inhibitors, conventional cytotoxic agents or a miscellaneous agent selected from abiraterone, ARN-509 and MYC inhibitors.
    这项发明涉及一种药物组合物,包括化合物(I)或其药学上可接受的盐,以及从信号转导途径抑制剂、肿瘤免疫治疗药物、抑制BCL2蛋白家族的药物、抑制Mcl-1的药物、蛋白酶抑制剂、聚(ADP核糖)聚合酶(PARP)抑制剂、芳香化酶抑制剂、传统细胞毒药物或从阿比特龙、ARN-509和MYC抑制剂中选择的杂项药物中选择的至少一种第二药剂。
  • Antibacterial 1-oxo-benzoquinolizine-2-carboxylic acids
    申请人:Warner-Lambert Company
    公开号:US04550103A1
    公开(公告)日:1985-10-29
    Novel 10-amino-9-fluoro- and 9-fluoro-6,7-dihydro-5-methyl-1-oxo-8-(heterocyclyl)1H,5H-benzo (ij)-2-carboxylic acids as antibacterial agents are described as well as methods for their manufacture, formulation, and use in treating bacterial infections.
    描述了一种新颖的10-基-9-和9--6,7-二氢-5-甲基-1-氧代-8-(杂环基)1H,5H-苯并(ij)-2-羧酸作为抗菌剂,以及它们的制造、配方和用于治疗细菌感染的方法。
查看更多

同类化合物

8-氧代-2,7-二氮杂螺[4,4]壬烷-2-甲酸叔丁酯 7-苄基-2,7- 二氮杂螺[4,4]壬烷-3-酮 6-氧代-2,7-二氮杂螺[4,4]壬烷-2-甲酸叔丁酯 2-甲基-7-苄基-2,7-二氮杂螺[4.4]壬烷 2-甲基-7-苄基-2,7-二氮杂螺[4.4]-1,3,8-壬三酮 2-甲基-2,7-二氮杂螺[4.4]壬烷-1,3,8-三酮 2-甲基-2,7-二氮杂螺[4.4]壬烷 2-甲基-2,6-二氮杂螺[3.4]辛烷草酸盐 2-氧代-1,7-二氮杂螺[4.4]壬烷-7-羧酸叔丁酯 2-乙基-7-苄基-2,7-二氮杂螺[4.4]壬烷 2-乙基-2,7-二氮杂螺[4,4]壬烷 2-BOC-2,7-二氮杂-螺[4.4]壬烷 2-(苯基甲基)-2,7-二氮杂螺[4.4]壬烷 2,7-二苄基-2,7-二氮杂-螺[4.4]壬烷 2,7-二氮杂螺[4.4]壬烷-2-羧酸 1,1-二甲基乙酯盐酸盐 2,7-二氮杂螺[4.4]壬烷-1,3,6,8-四酮 2,7-二氮杂螺[4.4]壬烷, 2-甲基-,双盐酸盐 2,7-二氮杂螺[4.4]壬烷 2,7-二氮杂螺[4.4]-3-壬酮 2,7-二氮杂螺[4.4]-3,8-壬二酮 2,7-二氮杂-螺[4.4]壬烷-1,3,8-三酮 1-苄基-1,7-二氮杂螺[4.4]壬烷-7-羧酸叔丁酯 1-苄基-1,7-二氮杂螺[4.4]壬烷 1-苄基-1,7-二氮杂-螺[4.4]壬烷二盐酸盐 1-甲基-1,7-二氮杂螺[4.4]壬烷二盐酸盐 1-甲基-1,7-二氮杂螺[4.4]壬烷 1,7-二氮杂螺[4.4]壬烷双盐酸盐 1,7-二氮杂螺[4.4]壬烷-7-羧酸叔丁酯 1,7-二氮杂螺[4.4]壬烷-1-羧酸 1,1-二甲基乙酯 1,7-二氮杂螺[4.4]壬烷 1,6-二氮杂-螺[4.4]壬烷-2,7-二酮 (9CI)-螺[1-氮杂双环[2.2.1]庚烷-7,3-吡咯烷] 2,7-Diazaspiro[4.4]nonane-2-carboxylic acid, 6-(fluoromethyl)-, 1,1-dimethylethyl ester, (5R,6S)-rel- 2-(ethylsulfonyl)-2,7-diazaspiro[4.4]nonane (5S)-7-methyl-1,7-diaza-spiro[4.6]undecane 6-(6-Chloropyridin-3-yl)-1,6-diazaspiro[3.4]octane (5RS,10RS)-2-benzyl-10-hydroxymethyl-2-azaspiro<4.5>dec-7-en-one 3,5-diamino-6-chloropyrazine-2-carboxylic acid [8-(4-oxo-4-pyrrolidin-1-yl-butyryl)-1,3,8-triazaspiro[4.5]dec-(2E)-ylidene]amide (5RS,10RS)-2-benzyl-10-hydroxymethyl-2-azaspiro<4.5>dec-7-ene 4-((1H-indol-3-yl)methyl)-9-(4-methylpyrimidin-2-yl)-1,4,9-triazaspiro[5.5]undecan-5-one 2-hydroxy-1-[7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[4.4]nonan-1-yl]ethanone N-(2-cyanoethyl)-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[4.4]nonane-1-carboxamide 1-[7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[4.4]nonane-1-carbonyl]pyrrolidine-3-carbonitrile 1,1-Dimethylethyl 7-[(6-{[E)-(3,4-difluorophenyl)[(ethyloxy)imino]methyl}-3-pyridinyl)methyl]-2,7-diazaspiro[4.4]nonane-2-carboxylate 2,7-Diazaspiro[4.4]nonane-2-ethanol (R)-7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane (R)-mandelate 7-(4-methoxy-6-methylpyrimidin-2-yl)-2-((2-methyl-5-(m-tolyl)-2H-1,2,3-triazol-4-yl)methyl)-2,7-diazaspiro[4,4]nonan-1-one (R)-4-cyclopentyl-6-(1,7-diaza-spiro[4.4]non-7-yl)-pyrimidin-2-ylamine 4-(1-benzyl-1,7-diazaspiro[4.4]non-7-yl)-6-cyclopentylpyrimidin-2-amine 2-(pyridin-4-yl)-2,7-diazaspiro[4.4]nonane